Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
about
Risk stratification in therapy-related myelodysplastic syndromes.Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?
P2860
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Comparison of clinical outcome ...... Clinical Research Consortium.
@en
Comparison of clinical outcome ...... Clinical Research Consortium.
@nl
type
label
Comparison of clinical outcome ...... Clinical Research Consortium.
@en
Comparison of clinical outcome ...... Clinical Research Consortium.
@nl
prefLabel
Comparison of clinical outcome ...... Clinical Research Consortium.
@en
Comparison of clinical outcome ...... Clinical Research Consortium.
@nl
P2093
P2860
P356
P1433
P1476
Comparison of clinical outcome ...... Clinical Research Consortium.
@en
P2093
A M Zeidan
D P Steensma
G Garcia-Manero
J E Lancet
M A Sekeres
P2860
P2888
P304
P356
10.1038/LEU.2017.33
P577
2017-01-23T00:00:00Z